|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating activities | |||||
| Net loss attributable to ordinary shareholders | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Share-based compensation | |||||
| Depreciation and amortization | |||||
| Realized gain on other investments | |||||
| Interest and gain on redemption of Series A-1 Preferred Shares | |||||
| Interest and gain on redemption of loan receivable | |||||
| SurancePlus fee income | |||||
| Change in fair value of equity securities | |||||
| Change in fair value of other investments | |||||
| Income attributable to non-controlling interests | |||||
| Change in operating assets and liabilities: | |||||
| Operating right-of-use asset | |||||
| Operating lease liability | |||||
| Premiums receivable | |||||
| Due from related parties | |||||
| Deferred policy acquisition costs | |||||
| Prepayment and other assets | |||||
| Prepaid offering costs | |||||
| Other Liabilities CatRe Tokenholders | |||||
| Losses payable | |||||
| Reserve for loss and loss adjustment expenses | |||||
| Unearned premiums reserve | |||||
| Accounts payable and other liabilities | |||||
| Net cash used in operating activities | |||||
| Investing activities | |||||
| Purchase of loan receivable | |||||
| Proceeds (funding) of loan receivable | |||||
| Proceeds of loan receivable | |||||
| Proceeds on redemption of Series A-1 preferred stock | |||||
| Proceeds from sale of equity securities | |||||
| Proceeds from sale of other investments | |||||
| Purchase of property and equipment | |||||
| Net cash provided by investing activities | |||||
| Financing activities | |||||
| Net proceeds from issuance of ordinary shares | |||||
| Partial redemption of notes payable to noteholders | |||||
| Gross proceeds from the issuance of Epsilon / DeltaCat Re tokens | |||||
| Tokenholders | |||||
| Net proceeds from the issuance of tokens | |||||
| Net cash provided by financing activities | |||||
| Cash and cash equivalents, and restricted cash and cash equivalents at beginning of year | |||||
| Cash and cash equivalents, and restricted cash and cash equivalents at end of year | |||||
| Net change during the year | |||||
| Balance at beginning of year | |||||
| Balance at end of year | |||||
| Non-cash investing activities | |||||
| Reclassification of contributed non-controlling interest | |||||
| Right-of-use lease asset obtained in exchange for operating lease liabilities | |||||
Loading...